OrbiMed’s NASH Terns

Terns Pharmaceuticals Inc. brings a dual U.S.-China strategy and a diverse pipeline to OrbiMed’s non-alcoholic steatohepatitis investment portfolio.

OrbiMed co-led the biotech’s $80 million series B on Oct. 30 with fellow new investor Vivo Capital. Decheng Capital, also a new investor, and existing investor Lilly Asia Ventures also participated. ...